Notes / Company

Lupin Ltd.

LUPIN BSE 500257 ISIN INE326A01037 Pharmaceuticals

Fundamentals

Market cap: ₹1.04 lakh cr
P/E: 16.39×
ROE: 19.08%
Debt / equity: 0.30
Div yield: 0.79%
52-week range: 1836.80 — 2494.00

Research on Tijori Finance

The timeline — 1 note on Lupin Ltd.

May 2026

22 May 26 · 15:54 IST Brief

Brief

Lupin wins its first drug approval in China

The company cleared Oseltamivir Phosphate Oral Suspension for the Chinese market, marking a quiet start to its entry in the region.

Verify on exchange BSE filings for LUPIN NSE filings for LUPIN Tijori Finance company page